All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
"Like clockwork, Amgen just finds a way," Piper Jaffray's Christopher Raymond headlined his hot comment on second-quarter earnings from Amgen Inc. Numbers from the Thousand Oaks, Calif-based company were solid, if not spectacular. Quarterly revenues increased 4 percent, to $6.1 billion, over the second quarter of 2017, and global product sales, which included the company's first biosimilar, Kanjinti, grew 2 percent.